129.16
-0.02 (-0.02%)
| Previous Close | 129.18 |
| Open | 130.37 |
| Volume | 13,414,416 |
| Avg. Volume (3M) | 6,116,966 |
| Market Cap | 160,361,168,896 |
| Price / Earnings (TTM) | 17.57 |
| Price / Earnings (Forward) | 15.22 |
| Price / Sales | 5.45 |
| Price / Book | 6.82 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2026 |
| TTM Dividend Yield | 2.49% |
| Profit Margin | 20.76% |
| Operating Margin (TTM) | 38.49% |
| Diluted EPS (TTM) | 4.76 |
| Quarterly Revenue Growth (YOY) | -0.30% |
| Quarterly Earnings Growth (YOY) | 24.80% |
| Total Debt/Equity (MRQ) | 130.79% |
| Current Ratio (MRQ) | 1.37 |
| Operating Cash Flow (TTM) | 10.37 B |
| Levered Free Cash Flow (TTM) | 9.99 B |
| Return on Assets (TTM) | 12.14% |
| Return on Equity (TTM) | 32.65% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - General (US) | Bullish | Mixed |
| Drug Manufacturers - General (Global) | Bullish | Mixed | |
| Stock | Gilead Sciences, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -0.5 |
| Average | 0.88 |
|
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics). |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Investment Style | Large Value |
| % Held by Insiders | 0.10% |
| % Held by Institutions | 89.79% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 20 Apr 2026 | CNBC | Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion |
| 03 Apr 2026 | CNBC | Trump tariff fallout: Some industries grapple with lingering effects one year later |
| TTM Dividend Yield | 2.49% |
| 5Y Average Dividend Yield | 3.38% |
| Payout Ratio | 65.13% |
| Expected Next Dividend Payment | Sep 2026 |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 15 Jun 2026 | 29 Apr 2026 | 29 Jun 2026 | 0.82 Cash |
| 13 Mar 2026 | 04 Feb 2026 | 30 Mar 2026 | 0.82 Cash |
| 15 Dec 2025 | 28 Oct 2025 | 30 Dec 2025 | 0.79 Cash |
| 15 Sep 2025 | 29 Jul 2025 | 29 Sep 2025 | 0.79 Cash |
| 13 Jun 2025 | 22 Apr 2025 | 27 Jun 2025 | 0.79 Cash |
| 14 Mar 2025 | 05 Feb 2025 | 28 Mar 2025 | 0.79 Cash |
| 13 Dec 2024 | 30 Oct 2024 | 30 Dec 2024 | 0.77 Cash |
| 13 Sep 2024 | 30 Jul 2024 | 27 Sep 2024 | 0.77 Cash |
| 14 Jun 2024 | 23 Apr 2024 | 27 Jun 2024 | 0.77 Cash |
| 14 Mar 2024 | 01 Feb 2024 | 28 Mar 2024 | 0.77 Cash |
| 14 Dec 2023 | 01 Nov 2023 | 28 Dec 2023 | 0.75 Cash |
| 14 Sep 2023 | 25 Jul 2023 | 28 Sep 2023 | 0.75 Cash |
| 14 Jun 2023 | 25 Apr 2023 | 29 Jun 2023 | 0.75 Cash |
| 14 Mar 2023 | 25 Jan 2023 | 30 Mar 2023 | 0.75 Cash |
| 14 Dec 2022 | 25 Oct 2022 | 29 Dec 2022 | 0.73 Cash |
| 14 Sep 2022 | 25 Jul 2022 | 29 Sep 2022 | 0.73 Cash |
| 14 Jun 2022 | 27 Apr 2022 | 29 Jun 2022 | 0.73 Cash |
| 14 Mar 2022 | 28 Jan 2022 | 30 Mar 2022 | 0.73 Cash |
| 14 Dec 2021 | 26 Oct 2021 | 30 Dec 2021 | 0.71 Cash |
| 14 Sep 2021 | 26 Jul 2021 | 29 Sep 2021 | 0.71 Cash |
| 14 Jun 2021 | 27 Apr 2021 | 29 Jun 2021 | 0.71 Cash |
| 12 Mar 2021 | 02 Feb 2021 | 30 Mar 2021 | 0.71 Cash |
| 14 Dec 2020 | 26 Oct 2020 | 30 Dec 2020 | 0.68 Cash |
| 14 Sep 2020 | 29 Jul 2020 | 29 Sep 2020 | 0.68 Cash |
| 11 Jun 2020 | 29 Apr 2020 | 29 Jun 2020 | 0.68 Cash |
| 12 Mar 2020 | 03 Feb 2020 | 30 Mar 2020 | 0.68 Cash |
| 12 Dec 2019 | 23 Oct 2019 | 30 Dec 2019 | 0.63 Cash |
| 12 Sep 2019 | 29 Jul 2019 | 27 Sep 2019 | 0.63 Cash |
| 13 Jun 2019 | 01 May 2019 | 27 Jun 2019 | 0.63 Cash |
| 14 Mar 2019 | 01 Feb 2019 | 28 Mar 2019 | 0.63 Cash |
| 13 Dec 2018 | 24 Oct 2018 | 28 Dec 2018 | 0.57 Cash |
| 13 Sep 2018 | 24 Jul 2018 | 27 Sep 2018 | 0.57 Cash |
| 14 Jun 2018 | 30 Apr 2018 | 28 Jun 2018 | 0.57 Cash |
| 15 Mar 2018 | 05 Feb 2018 | 29 Mar 2018 | 0.57 Cash |
| 14 Dec 2017 | 25 Oct 2017 | 28 Dec 2017 | 0.52 Cash |
| 14 Sep 2017 | 25 Jul 2017 | 28 Sep 2017 | 0.52 Cash |
| 14 Jun 2017 | 01 May 2017 | 29 Jun 2017 | 0.52 Cash |
| 14 Mar 2017 | 06 Feb 2017 | 30 Mar 2017 | 0.52 Cash |
| 13 Dec 2016 | 31 Oct 2016 | 29 Dec 2016 | 0.47 Cash |
| 14 Sep 2016 | 22 Jul 2016 | 29 Sep 2016 | 0.47 Cash |
| 14 Jun 2016 | 27 Apr 2016 | 29 Jun 2016 | 0.47 Cash |
| 14 Mar 2016 | 02 Feb 2016 | 30 Mar 2016 | 0.43 Cash |
| 14 Dec 2015 | 26 Oct 2015 | 30 Dec 2015 | 0.43 Cash |
| 14 Sep 2015 | 23 Jul 2015 | 29 Sep 2015 | 0.43 Cash |
| 12 Jun 2015 | 24 Apr 2015 | 29 Jun 2015 | 0.43 Cash |
| Show more | |||
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2026 | 1.64 | 2 | 1.27 |
| 2025 | 3.16 | 4 | 2.58 |
| 2024 | 3.08 | 4 | 3.33 |
| 2023 | 3.00 | 4 | 3.70 |
| 2022 | 2.92 | 4 | 3.40 |
| 2021 | 2.84 | 4 | 3.91 |
| 2020 | 2.72 | 4 | 4.67 |
| 2019 | 2.52 | 4 | 3.88 |
| 2018 | 2.28 | 4 | 3.65 |
| 2017 | 2.08 | 4 | 2.90 |
| 2016 | 1.84 | 4 | 2.57 |
| 2015 | 1.29 | 3 | 1.28 |
| Show more | |||
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |